ABSTRACT

Introduction: Colorectal cancer (CRC) is a major public health problem. Despite major progress understanding the biological basis of this tumor added to the incorporation of optimized diagnostic and therapeutic strategies, prognosis after progression on first-line standard treatment remains poor. Several antiangiogenic treatments have demonstrated improvement in overall survival (OS) in the second-line treatment being aflibercept, a fully humanized recombinant protein, one of them. The results of the VELOUR study showed that the addition of aflibercept to second-line FOLFIRI improved OS and progression-free survival.

Areas covered: A literature review of published clinical studies was performed in order to discuss the clinical data on aflibercept in mCRC from early drug development to real-world data.

Expert opinion: The combination of aflibercept with FOLFIRI provides a statistical improvement in OS and in all the efficacy endpoints analyzed in the VELOUR trial, showing efficacy independently on time to progression, molecular status, prior biological treatment, or age. Further studies are needed to find new biomarkers and molecular characterization in order to better select patients that could benefit from this treatment.

摘要

简介： 结直肠癌（CRC）是一个重大的公共卫生问题。尽管在了解这种肿瘤的生物学基础方面取得了重大进展，并结合了优化的诊断和治疗策略，但一线标准治疗进展后的预后仍然很差。几种抗血管生成治疗已证明在二线治疗中总生存期（OS）的改善是阿柏西普，一种完全人源化的重组蛋白，其中之一。VELOR 研究的结果表明，在二线 FOLFIRI 中添加阿柏西普可改善 OS 和无进展生存期。

涵盖的领域：对已发表的临床研究进行了文献回顾，以讨论从早期药物开发到真实世界数据的 mCRC 中阿柏西普的临床数据。

专家意见：阿柏西普与 FOLFIRI 的组合提供了 OS 和 VELOR 试验中分析的所有疗效终点的统计改善，显示出独立于进展时间、分子状态、先前生物治疗或年龄的疗效。需要进一步的研究来寻找新的生物标志物和分子特征，以便更好地选择可以从这种治疗中受益的患者。